Strides Arcolab, one of India's largest exporters of branded generic pharmaceutical products, has announced receipt of ANDA approval for Rifampicin Injection USP, 600 mg   dose vial.

Rifampin is a semi-synthetic antibiotic indicated for the treatment of tuberculosis and meningococcal carriers.

The product is licensed to Akorn-Strides, LLC, which is a Joint Venture that was funned in 2004 by Akorn, Inc and Strides Arcolab Ltd.

The primary mission for the Joint Venture is to develop liquid, lyophilized and dry powder formulations of generic injectable products targeting several therapeutic markets with a major focus on anti-infective, analgesics and CNS medicines.

Strides Acrolab has a major presence in various developing countries such as Africa, Latin America and Asia as well as in developed markets such as the U.S., Canada and part of Europe. The company is one of the largest Indian suppliers of institutionally funded aid projects and is an approved supplier to the Global Drug Facility, UNICEF, and MSF amongst others.